Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ironwood Pharmaceuticals Trading Up 3.2 %

NASDAQ:IRWD opened at $1.94 on Thursday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $1.59 and a 1 year high of $15.70. The firm’s fifty day simple moving average is $3.63 and its 200 day simple moving average is $4.18.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. raised its stake in Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after purchasing an additional 450,949 shares during the last quarter. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after purchasing an additional 677,024 shares in the last quarter. Geode Capital Management LLC boosted its position in Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock valued at $14,652,000 after buying an additional 13,028 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock worth $8,786,000 after acquiring an additional 78,969 shares in the last quarter. Finally, Stonepine Capital Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 1,982.8% during the third quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after purchasing an additional 951,988 shares during the last quarter.

Analyst Upgrades and Downgrades

IRWD has been the subject of a number of recent analyst reports. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. JMP Securities lowered their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Finally, Craig Hallum dropped their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.